Get the Weekly Intelligence Brief — top committee picks every Sunday.

ARGX vs DNTH

argenx SE vs Dianthus Therapeutics, Inc. — AI-powered side-by-side comparison
ARGX
argenx SE
69
Buy
VS
DNTH
Dianthus Therapeutics, Inc.
54
Watch
MetricARGXDNTH
AI Score 69 54
Price $864.40 $108.40
P/E Ratio 31.34× -834.54×
ROE 17.6% -32.9%
Revenue Growth YoY
Gross Margin 89.9% 96.0%
Debt / Equity 0.01× 0.00×
Dividend Yield 0.0% 0.0%
RSI (14) 47.9 52.5
Beta -0.022 0.082
Expected Upside

AI Committee View

Current Innellis committee reasoning for ARGX versus DNTH.
ARGX leads by 15 points.

ARGX scores 69/100 (Buy) versus DNTH at 54/100 (Watch).

ARGX Committee View
67% agreement
6 analysts

The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 22.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
  • EPS growing 95.7% YoY — Growth
Bear Case
  • Price-to-book of 6.9x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
DNTH Committee View
50% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -60.8% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
  • ROE of only -22.5% -- cheap may mean cheap for a reason — Value
  • Revenue declining -60.8% YoY -- this is not a growth story right now — Growth
  • MACD histogram negative -- bearish momentum — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ARGX Full Analysis DNTH Full Analysis